Mar 31, 2026 8:16 am EDT VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
Mar 30, 2026 8:13 am EDT Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Mar 26, 2026 8:17 am EDT Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
Mar 25, 2026 4:12 pm EDT VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update
Mar 18, 2026 8:17 am EDT Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA
Mar 6, 2026 8:10 am EST Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
Feb 9, 2026 5:20 pm EST VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
